These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11739829)

  • 1. Prospective longitudinal assessment of hallucinations in Parkinson's disease.
    Goetz CG; Leurgans S; Pappert EJ; Raman R; Stemer AB
    Neurology; 2001 Dec; 57(11):2078-82. PubMed ID: 11739829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
    Goetz CG; Wuu J; Curgian L; Leurgans S
    Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
    Aarsland D; Larsen JP; Tandberg E; Laake K
    J Am Geriatr Soc; 2000 Aug; 48(8):938-42. PubMed ID: 10968298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine treatment for dopaminergic-induced hallucinations.
    Ondo WG; Levy JK; Vuong KD; Hunter C; Jankovic J
    Mov Disord; 2002 Sep; 17(5):1031-5. PubMed ID: 12360554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease--a prospective study.
    Happe S; Berger K;
    J Neurol; 2001 Dec; 248(12):1062-7. PubMed ID: 12013583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.
    Goetz CG; Wuu J; Curgian LM; Leurgans S
    Neurology; 2005 Jan; 64(1):81-6. PubMed ID: 15642908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations.
    Santangelo G; Trojano L; Vitale C; Ianniciello M; Amboni M; Grossi D; Barone P
    Mov Disord; 2007 Dec; 22(16):2418-25. PubMed ID: 17894370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
    Sawada H; Oeda T; Umemura A; Tomita S; Hayashi R; Kohsaka M; Yamamoto K; Sudoh S; Sugiyama H
    PLoS One; 2014; 9(1):e85886. PubMed ID: 24497930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hallucinations in Parkinson's disease using a novel scale.
    Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K
    Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders].
    Wu DD; Li SH; Jin LY; Jin Y; Cui YY; Zhao H; Liu HJ; Ma XX; Su W; Chen HB
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(13):1016-20. PubMed ID: 27055793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
    Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
    Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease.
    Llebaria G; Pagonabarraga J; Martínez-Corral M; García-Sánchez C; Pascual-Sedano B; Gironell A; Kulisevsky J
    Mov Disord; 2010 Dec; 25(16):2785-91. PubMed ID: 20960483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study.
    Goetz CG; Ouyang B; Negron A; Stebbins GT
    Neurology; 2010 Nov; 75(20):1773-9. PubMed ID: 20962287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.